```html

Wegener’s Granulomatosis (Granulomatosis with Polyangiitis)

Overview

Granulomatosis with polyangiitis (GPA), historically called Wegener’s granulomatosis, is a rare, systemic autoimmune disease characterized by inflammation of small‑ and medium‑sized blood vessels (vasculitis) and the formation of granulomas—clusters of inflammatory cells—in the respiratory tract and kidneys. The disease can affect virtually any organ, but the classic triad involves the upper airway (sinuses, nose, ear), lungs, and kidneys.

• Incidence: Approximately 3–4 new cases per million people each year worldwide.
• Prevalence: Roughly 20–60 cases per million in the United States and Europe.
• Age: Most commonly diagnosed between ages 40‑65, but children and older adults can be affected.
• Sex: Slight male predominance (≈55 % men).
• Geography: Seen worldwide; higher rates reported in Northern Europe and North America.

Because GPA can progress rapidly, early recognition and treatment are essential to prevent irreversible organ damage.

Symptoms

Symptoms depend on which organs are involved and may appear gradually or suddenly. Below is a comprehensive list with brief explanations.

Upper Respiratory Tract

• Chronic sinusitis – nasal congestion, facial pain, and discharge that does not improve with antibiotics.
• Nasal crusting or ulceration – painful crusts, occasional nosebleeds (epistaxis).
• Ear involvement – hearing loss, ear pain, or fluid buildup (serous otitis media).
• Sore throat & hoarseness – due to granulomatous inflammation of the larynx.

Lungs

• Cough – often dry but can become productive if infection occurs.
• Shortness of breath – especially during exertion.
• Chest pain – pleuritic (sharp) pain caused by lung inflammation.
• Hemoptysis – coughing up blood, ranging from streaks to larger amounts.
• Diffuse nodules or cavitary lesions visible on chest imaging.

Kidneys

• Hematuria – blood in the urine, often microscopic.
• Proteinuria – excess protein in urine, indicating kidney inflammation.
• Edema – swelling of the legs, ankles, or face due to fluid retention.
• Decreased urine output – a sign of worsening kidney function.

Other Organ Systems

• Skin – palpable purpura, ulcerations, or livedo reticularis.
• Eyes – scleritis, conjunctivitis, or vision loss.
• Peripheral nerves – mononeuritis multiplex causing patchy numbness or weakness.
• Gastrointestinal tract – abdominal pain, melena, or perforation (rare).
• Joint pain – arthralgias without swelling.
• General symptoms – fever, fatigue, weight loss, night sweats.

Causes and Risk Factors

The exact trigger for GPA is unknown, but research points to a combination of genetic susceptibility, environmental exposure, and immune system dysregulation.

Immunologic Mechanisms

• ANCA antibodies – >90 % of patients have anti‑proteinase 3 (PR3‑ANCA, formerly c‑ANCA). These auto‑antibodies activate neutrophils, leading to vessel damage.
• Granuloma formation – a T‑cell mediated response that creates localized inflammatory masses.

Genetic Factors

• HLA‑DPB1*04:01 and HLA‑DPA1*03:01 alleles increase susceptibility (studies from NIH and European cohorts).
• Family clustering is rare, but first‑degree relatives have a modestly higher risk.

Environmental Triggers

• Silica dust exposure – occupational exposure (mining, construction) is linked to higher ANCA‑associated vasculitis rates.
• Infections – Staphylococcus aureus colonization of the nose is associated with disease relapses.
• Medications – Rarely, drugs like propylthiouracil or hydralazine can induce ANCA vasculitis that mimics GPA.

Who Is at Higher Risk?

• Adults aged 40‑65, especially males.
• Individuals with a history of chronic sinus disease.
• People with prolonged silica exposure or occupational dust inhalation.
• Patients with other autoimmune diseases (e.g., rheumatoid arthritis) have a slightly increased risk.

Diagnosis

Diagnosing GPA requires a combination of clinical suspicion, laboratory testing, imaging, and tissue confirmation.

Clinical Evaluation

• Detailed history focusing on ENT, pulmonary, renal, and systemic symptoms.
• Physical examination for nasal ulcers, lung crackles, skin lesions, and joint findings.

Laboratory Tests

• ANCA testing – indirect immunofluorescence and ELISA for PR3‑ANCA (c‑ANCA) is the most specific test; ~90 % sensitivity in active disease.
• Complete blood count (CBC) – may reveal anemia or leukocytosis.
• Serum creatinine & eGFR – assess kidney function.
• Urinalysis – look for hematuria, proteinuria, or red‑cell casts.
• Inflammatory markers – ESR and CRP are usually elevated.

Imaging Studies

• Chest X‑ray – nodules, cavitations, or infiltrates.
• High‑resolution CT (HRCT) of the chest – more sensitive for early lung lesions.
• Sinus CT – mucosal thickening, bony erosion, or granulomatous masses.
• Renal ultrasound – optional, to assess kidney size.

Histopathology (Biopsy)

Definitive diagnosis usually requires tissue from an affected site (e.g., nasal mucosa, lung, kidney). Classic findings:

• Necrotizing granulomas.
• Vasculitis of small‑ to medium‑sized vessels.
• Absence of immune complex deposition (pauci‑immune).

When kidney involvement is suspected, a percutaneous renal biopsy is often performed.

Classification Criteria

The 2022 ACR/EULAR GPA classification criteria assign points based on ANCA status, imaging, and biopsy results. A score ≥ 5 classifies the patient as having GPA (see Kerr et al., 2022).

Treatment Options

Therapy aims to induce remission, then maintain it while minimizing drug toxicity. Treatment is usually coordinated by a rheumatologist, pulmonologist, and nephrologist.

Induction Therapy (remission induction)

• Glucocorticoids – high‑dose oral prednisone (1 mg/kg/day) or intravenous methylprednisolone (500–1000 mg/day for 3 days) followed by taper.
• Cyclophosphamide – oral (2 mg/kg/day) or IV pulse (15 mg/kg) for 3–6 months; highly effective for severe organ involvement.
• Rituximab – anti‑CD20 monoclonal antibody (375 mg/m² weekly × 4 or 1 g on days 1 and 15); comparable efficacy to cyclophosphamide, preferable in young patients or those desiring fertility preservation.
• Plasma exchange (PLEX) – considered for severe renal disease (creatinine > 5 mg/dL) or pulmonary hemorrhage; evidence from the PEXIVAS trial suggests modest benefit.

Maintenance Therapy (preventing relapse)

• Azathioprine – 2 mg/kg/day.
• Mycophenolate mofetil – 1–1.5 g twice daily.
• Rituximab – 500 mg IV every 6 months for 2–5 years (based on relapse risk).
• Methotrexate – 15–25 mg weekly (if renal function permits).
• Low‑dose glucocorticoids (≤ 10 mg prednisone) are usually continued for the first 6–12 months.

Adjunctive Measures

• Trimethoprim‑sulfamethoxazole (TMP‑SMX) – prophylaxis against Pneumocystis jirovecii pneumonia (PCP) and may reduce nasal S. aureus colonization.
• Vaccinations – influenza, pneumococcal, COVID‑19, and hepatitis B before initiating immunosuppression.
• Bone health – calcium, vitamin D, and bisphosphonates if long‑term steroids are used.

Lifestyle & Supportive Care

• Smoking cessation – smoking worsens lung disease and impairs medication efficacy.
• Balanced diet rich in protein and nutrients to counteract steroid‑related weight gain and muscle loss.
• Regular exercise (as tolerated) to maintain cardiovascular health.
• Psychological support – chronic disease can lead to anxiety or depression; counseling or support groups are beneficial.

Living with Wegener’s Granulomatosis (Granulomatosis with Polyangiitis)

Long‑term management focuses on monitoring disease activity, minimizing medication side effects, and maintaining quality of life.

Self‑Monitoring

• Track symptoms daily (sinus pain, cough, urine changes, fatigue).
• Keep a medication log, noting doses and any side effects.
• Check blood pressure and weight weekly.
• Perform home urine dip tests (if advised) for early detection of hematuria.

Regular Follow‑Up

• Rheumatology visits every 1‑3 months during induction; every 3‑6 months for maintenance.
• Laboratory panel (CBC, creatinine, eGFR, urinalysis, ANCA titer) at each visit.
• Chest X‑ray or CT every 6‑12 months if lung disease was present.
• Dental and ENT evaluations annually, or sooner if sinus symptoms recur.

Managing Medication Side Effects

• Glucocorticoids: Watch for mood changes, hyperglycemia, osteoporosis, and infection risk. Use the lowest effective dose.
• Cyclophosphamide: Monitor blood counts, urinalysis for hemorrhagic cystitis, and counsel on fertility preservation (e.g., sperm banking).
• Rituximab: Pre‑infusion labs (CBC, immunoglobulins) and infection prophylaxis.
• Report persistent mouth sores, unusual bruising, or severe fatigue to your physician promptly.

Practical Tips

• Carry a **medical alert card** indicating GPA, current medications, and ANCA status.
• Plan travel ahead: bring enough medication, a copy of prescriptions, and a letter from your doctor.
• Stay hydrated and avoid excessive alcohol, which can increase kidney stress.
• Use saline nasal sprays or rinses to keep nasal passages moist and reduce crusting.
• Engage in low‑impact activities (walking, swimming, yoga) to maintain stamina without overtaxing joints.

Prevention

Because GPA’s exact cause is unknown, primary prevention is limited. However, certain measures can lower the risk of disease onset or relapse:

• Avoid silica dust – use protective equipment in high‑risk jobs.
• Prompt treatment of chronic sinus infections – reduces bacterial colonization that may trigger relapses.
• Vaccinations – lower the chance of infections that can precipitate disease flares.
• Smoking cessation – reduces respiratory irritation and improves treatment response.
• Regular medical follow‑up – early detection of a flare can prevent organ damage.

Complications

If left untreated or inadequately controlled, GPA can lead to serious, often irreversible complications:

• Renal failure – rapidly progressive glomerulonephritis can require dialysis or transplantation.
• Chronic lung disease – fibrosis, bronchiectasis, or permanent cavitary lesions.
• Permanent hearing loss – due to recurring middle‑ear inflammation.
• Vision loss – from scleritis or optic nerve involvement.
• Neuropathy – persistent nerve damage causing weakness or sensory loss.
• Infections – immunosuppression raises risk for bacterial, viral, and opportunistic infections.
• Thromboembolic events – vasculitis‑related endothelial injury increases clot risk.
• Malignancy – long‑term cyclophosphamide use is associated with bladder cancer and hematologic malignancies.

When to Seek Emergency Care

---

**Sources:** Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, Kerr et al., 2022, NEJM, PEXIVAS Trial, 2020, American College of Rheumatology Guidelines (2021).

```